The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy. While major advances have been made in the disease, it is still incurable. Although antifolate-based drugs are not commonly used to treat myeloma, new generation analogs with distinct patterns of preclinical and clinical activit...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinahan, Cristina, Mangone, Michael A., Scotto, Luigi, Visentin, Michele, Marchi, Enrica, Cho, Hearn Jay, O’Connor, Owen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210016/
https://www.ncbi.nlm.nih.gov/pubmed/32405334
http://dx.doi.org/10.18632/oncotarget.27516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210016/
https://www.ncbi.nlm.nih.gov/pubmed/32405334
http://dx.doi.org/10.18632/oncotarget.27516

Ejemplares similares